A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma.
Benson DM Jr et al. Clin Cancer Res. 2015 May 21. pii: clincanres.0304.2015. [Epub ahead of print].
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.
Noonan KA et al. Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.
The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.
Suen H et al. Leukemia. 2015 May 19. doi: 10.1038/leu.2015.104. [Epub ahead of print].
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
McCann KJ et al. Cancer Immunol Immunother. 2015 May 16. [Epub ahead of print].
A Phase I Study of Thymoglobulin for Relapsed or Refractory Multiple Myeloma.
Keller J et al. Leuk Lymphoma. 2015 May 13:1-11. [Epub ahead of print].
Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
Savelieva M et al. Eur J Clin Pharmacol. 2015 Jun;71(6):663-72. doi: 10.1007/s00228-015-1846-7. Epub 2015 May 5.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Niesvizky R et al. Leuk Lymphoma. 2015 May 15:1-9. [Epub ahead of print].